These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29486991)

  • 1. Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Barrington DA; Champion ML; Boitano TKL; Walters-Haygood CL; Farmer MB; Alvarez RD; Estes JM; Leath CA
    Gynecol Oncol; 2018 May; 149(2):337-340. PubMed ID: 29486991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Boitano TKL; Barrington DA; Batra S; McGwin G; Turner TB; Farmer MB; Brown AM; Straughn MJ; Leath CA
    Gynecol Oncol; 2019 Aug; 154(2):379-382. PubMed ID: 31196574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics.
    Pal T; Bonner D; Kim J; Monteiro AN; Kessler L; Royer R; Narod SA; Vadaparampil ST
    Breast J; 2013; 19(2):189-92. PubMed ID: 23320992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    Lee SS; Karpel HC; Oh C; Smith J; Pothuri B
    Gynecol Oncol; 2023 Mar; 170():234-240. PubMed ID: 36724586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing for hereditary breast and ovarian cancer in the southeastern United States.
    Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
    Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.
    Greene MH; Piedmonte M; Alberts D; Gail M; Hensley M; Miner Z; Mai PL; Loud J; Rodriguez G; Basil J; Boggess J; Schwartz PE; Kelley JL; Wakeley KE; Minasian L; Skates S
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):594-604. PubMed ID: 18349277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care.
    Hong L; Gonzalez R; Unternaehrer J; Ioffe Y
    Gynecol Obstet Invest; 2020; 85(3):214-221. PubMed ID: 32203957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inherited predisposition to breast cancer among African American women.
    Churpek JE; Walsh T; Zheng Y; Moton Z; Thornton AM; Lee MK; Casadei S; Watts A; Neistadt B; Churpek MM; Huo D; Zvosec C; Liu F; Niu Q; Marquez R; Zhang J; Fackenthal J; King MC; Olopade OI
    Breast Cancer Res Treat; 2015 Jan; 149(1):31-9. PubMed ID: 25428789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
    J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    Lee EG; Kang HJ; Lim MC; Park B; Park SJ; Jung SY; Lee S; Kang HS; Park SY; Park B; Joo J; Han JH; Kong SY; Lee ES
    Cancer Res Treat; 2019 Jan; 51(1):280-288. PubMed ID: 29747489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.